Dr. Cetnar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3181 Sw Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-6346Fax+1 608-266-6020- Is this information wrong?
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2006 - 2009
Oregon Health & Science UniversityResidency, Internal Medicine, 2002 - 2005
Loyola University Chicago Stritch School of MedicineClass of 2002
Certifications & Licensure
OR State Medical License 2013 - 2025
WI State Medical License 2009 - 2013
PA State Medical License 2006 - 2010
MN State Medical License 2005 - 2006- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
- Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer Start of enrollment: 2012 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.Galsky, M., Daneshmand, S., Izadmehr, S., Gonzalez-Kozlova, E., Chan, K., Lewis, S., Achkar, B., Dorff, T., Cetnar, J., Neil, B., D'Souza, A., Mamtani, R., Kyriakopoul...> ;Nature Medicine. 2024 Jan 19
- PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refu...Chu, X., Cole, S., Gartrell, B., Woo, B., Li-Ning-Tapia, E., Grivas, P., Koshkin, V., Jain, R., Dreicer, R., Cetnar, J., Sundi, D., Galsky, M., Hahn, N., Carducci, M.> ;European Urology Oncology. 2023 Dec 27
- 10 citationsGemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.Galsky, M., Daneshmand, S., Izadmehr, S., Gonzalez-Kozlova, E., Chan, K., Lewis, S., Achkar, B., Dorff, T., Cetnar, J., Neil, B., D'Souza, A., Mamtani, R., Kyriakopoul...> ;Nature Medicine. 2023 Nov 1
- Join now to see all
Press Mentions
Gemcitabine, Cisplatin, plus Nivolumab in Patients with Muscle-Invasive Bladder Cancer with Selective Bladder SparingJune 15th, 2018
Professional Memberships
- Member
Hospital Affiliations
OHSU HospitalPortland, Oregon
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
